In-vitro studies revealed that nafamostat mesylate has antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and anti-inflammatory and anti-coagulation effect. However, there is no clinical studies on the efficacy of nafamostat in patients with COVID-19. This study is conducted to evaluate the clinical efficacy of nafamostate mesylate in adult patients hospitalized with COVID-19 pneumonia.
- The COVID-19 epidemic expanded to the whole world since it started from the Wuhan area
in China in Dec. 2019. The Republic of Korea experiences a sharp increase in the patient
since 24th Feb. 2020. An analysis of more than 70,000 patients in China, about 15% of
them cause severe pneumonia, 5% require treatment in the intensive care unit, half of
them die of the disease.
- There is no proven therapeutics for COVID-19 patients yet. Currently, the treatment with
Kaletra, Hydroxychloroquine, etc. did not show apparent effect, and there are no other
drugs that can apply to patients who get worse even with those drugs or severe.
- There are research reports that defective innate immunity and accelerated activation of
the complement cascade, caused by the SARS-CoV-2, induce rapidly progressing
pneumonitis.
- Action mechanism of Nafamostat mesilate A. Show anti-viral effect by an inhibition
serine protease, which is required for the host membrane fusion of viral envelop
protein. In vitro experiments showed that the drug is effective in MERS-CoV,
Influenza virus, and SARS-CoV-2.
B. Show anti-inflammatory effect by inhibition of the complement pathway, and inhibition of
cytokine production.
This study is conducted to evaluate the clinical efficacy of nafamostate mesylate in adult
patients hospitalized with COVID-19 pneumonia.
Drug: Nafamostat Mesylate
The Nafamostat mesilate group received continuous intravenous infusion of 0.1-0.2 mg/kg/h of nafamostat mesilate mixed with 5% DW.
- Inclusion Criteria:
1. 18 years old or older
2. Patients who have been confirmed of COVID-19 infection and has evidence for
pneumonia
- Confirmation of COVID-19 infection by RT-PCR of SARS-CoV-2
- Definite diagnosis of new infiltration of the lungs by chest CT scan of
chest radiographic inspection
3. Patients who are within 72 hours of COVID-19 pneumonia confirmation
4. Patients with 3(hospitalization, not requiring supplemental oxygen) or higher in
seven-category ordinal scale of clinical status
- Seven-category ordinal scale of clinical status
1. not hospitalized with resumption of normal activities;
2. not hospitalized, but unable to resume normal activities;
3. hospitalization, not requiring supplemental oxygen;
4. hospitalization, requiring supplemental oxygen;
5. hospitalization, requiring nasal high-flow oxygen therapy and/or
noninvasive mechanical ventilation;
6. hospitalization, requiring extracorporeal membrane oxygenation and/or
invasive mechanical ventilation;
7. death.
5. Patients who are eligible for diagnosis/evaluation to chest CT scan and related
to it
6. Patients should be able to understand the essence of the clinical trial and to
submit a written consent document. For the patients who can understand the nature
of the research but cannot sign the document, a relative can agree to the study.
- Exclusion Criteria:
1. Patients who have a record of HIV or AIDS
2. Female patients, either who are pregnant within 6 months before the
investigation, who breast-fed babies within 3 months before the investigation, or
who may get pregnant or breast-feed within 1 month after the investigation is
over
3. Patients at high risk of death within 3 days of randomized assignment, by the
judge of the investigator
4. Patients with liver cirrhosis whose Child-Puch score is B or C
5. Patients who have liver disease abnormalities with ALT or AST > 5 times ULN
6. Patients who can be in danger or who shows clinically-important other conditions
which may interfere with the evaluation or completion of the test procedure, as
the investigator's opinion
7. Patients who are not appropriate for the test, as the investigator's opinion
8. Patients who have hypersensitivity to the investigational drug
IN-GYU BAE, MD
+82-55-750-8055
ttezebae@gmail.com
Kyunglan Moon, MD
lannya@naver.com
IN-GYU BAE, MD, Principal Investigator
Gyeongsang National University Hospital